Skip to main content

Table 2 Patients’ responses evaluated at 8 weeks according to the RECIST criteria

From: Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer

Non-progression rate at 8 weeks (N = 45)

 Rate % (CI 95%)

48.9

(33.7–64.2)

Response at 8 weeks (N = 45)

 

N

%

 Response at 8 weeks (N = 32)

  Complete response

0

0.0

  Partial response

3

6.7

  Stable disease

19

42.2

  Progressive disease

10

22.2

Not evaluated 8 weeks (N = 13)